Cost analysis of the treatments for patients with advanced Parkinson's disease: SCOPE study

References

• Dorsey E, Constantinescu R, Thompson J, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007;68:384-6
   PubMed Web of Science ®Google Scholar
• Population figures and demographic censuses. National Institute of Statistics, Spain, 2010. http://www.ine.es/inebmenu/mnu_cifraspob.htm. Accessed March 9, 2012
   Google Scholar
• Claveria L, Duarte J, Sevillano M, et al. Prevalence of Parkinson's disease in Cantalejo, Spain: a door-to-door survey. Mov Disord 2002;17:242-9
   PubMed Web of Science ®Google Scholar
• Benito-Leon J, Bermejo-Pareja F, Rodriguez J, et al. Prevalence of PD and other types of parkinsonism in three elderly populations of central Spain. Mov Disord 2003;18:267-74
   PubMed Web of Science ®Google Scholar
• Bergareche A, De La Puente E, Lopez de Munain A, et al. Prevalence of Parkinson's disease and other types of Parkinsonism. A door-to-door survey in Bidasoa, Spain. J Neurol 2004;251:340-5
   PubMed Web of Science ®Google Scholar
• Abasolo-Osionaga E, Abecia-Inchaurregui L, Fernández-Díaz E, et al. The prevalence and pharmacological cost of Parkinson's disease in Spain. Rev Neurol 2006;43:641-5
   Google Scholar
• Kulisevsky J. Estimulación cerebral profunda en el tratamiento de la enfermedad de Parkinson: programa de actualización. 2nd edn. Profármaco, Barcelona, 2005
   Google Scholar
• Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448-58
   PubMed Web of Science ®Google Scholar
• Adler C. Relevance of motor complications in Parkinson's disease. Neurology 2002;58(4 Suppl 1):S51-6
   Google Scholar
• Oertel W, Berardelli A, Bloem B, et al. Late (complicated) Parkinson's disease. In: Gilhus N, Barnes M, Brainin M, eds. European Handbook of Neurological Management: Volume 1. 2nd edn. Blackwell Publishing Ltd, 2011
   Google Scholar
• Silberstein P, Bittar R, Boyle R, et al. Deep brain stimulation for Parkinson's disease: Australian referral guidelines. J Clin Neurosci 2009;16:1001-8
   Google Scholar
• Krack P, Batir A, Van Blercom N, et al. Five-year follow-up of bilateral stimulation of the subthalamic nucleus in advanced Parkinson's disease. N Engl J Med 2003;349:1925-34
   PubMed Web of Science ®Google Scholar
• Limousin P, Pollak P, Benazzouz A, et al. Effect on parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation. Lancet 1995;345:91-5
   PubMed Web of Science ®Google Scholar
• Limousin P, Krack P, Pollak P. Electrical stimulation of the subthalamic nucleus in complicated parkinson's disease. N Engl J Med 1998;339:1105-11
   PubMed Web of Science ®Google Scholar
• Rodriguez-Oroz M, Obeso J, Lang A, et al. Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 2005;128:2240-9
   PubMed Web of Science ®Google Scholar
• Schüpbach W, Chastan N, Welter M, et al. Stimulation of the subthalamic nucleus in Parkinson's disease: a 5 year follow-up. J Neurol Neurosurg Psychiatry 2005;76:1640-4
   PubMed Web of Science ®Google Scholar
• Pahwa R, Factor S, Lyons K, et al. Practice parameter: treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:983-5
   PubMed Web of Science ®Google Scholar
• Deuschl G, Schade-Brittinger C, Krack P, et al. A randomized trial of deep brain stimulation for Parkinson's disease. N Engl J Med 2006;355:896-908
   PubMed Web of Science ®Google Scholar
• Østergaard K, Sunde N. Evolution of Parkinson's disease during 4 years of bilateral deep brain stimulation of the subthalamic nucleus. Mov Disord 2006;21:624-31
   PubMed Web of Science ®Google Scholar
• Kleiner-Fisman G, Herzog J, Fisman DN, et al. Subthalamic nucleus deep brain stimulation: summary and meta-analysis of outcomes. Mov Disord 2006;21(14 Suppl):S290-304
   Google Scholar
• Gan J, Xie-Brustolin J, Mertens P, et al. Bilateral subthalamic nucleus stimulation in complicated parkinson's disease: three years follow-up. J Neurol 2007;254:99-106
   PubMedGoogle Scholar
• Weaver F, Follett K, Stern M, et al. Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson's disease. JAMA 2009;301:63-73
   PubMed Web of Science ®Google Scholar
• Williams A, Gill S, Varma T, et al. Deep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson's disease (PD SURG trial): a randomised, open-label trial. Lancet Neurol 2010;9(6):581-91
   PubMed Web of Science ®Google Scholar
• Clarke C, Worth P, Grosset D, et al. Systematic review of apomorphine infusion, levodopa infusion and deep brain stimulation in advanced Parkinson's disease. Parkisonism Rel Disord 2009;15:728-41
   PubMed Web of Science ®Google Scholar
• Antonini A, Isaias I, Canesi M, et al. Duodenal levodopa infusion for complicated parkinson's disease: 12-month treatment outcome. Mov Disord 2007;22:1145-9
   PubMed Web of Science ®Google Scholar
• Samanta J, Hauser R. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-64
   PubMed Web of Science ®Google Scholar
• McGee P. Apomorphine treatment: a nurse's perspective. ACNR 2002;2:23-4
   Google Scholar
• Manson A, Turner K, Lees A. Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: long-term follow-up study of 64 patients. Mov Disord 2002;17:1235-41
   PubMed Web of Science ®Google Scholar
• Katzenschlager R, Hughes A, Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005;20:151-7
   PubMed Web of Science ®Google Scholar
• Pietz K, Hagell P, Odin P. Subcutaneous apomorphine in late stage Parkinson's disease: a long term follow up. J Neurol Neurosurg Psychiatry 1998;65:709-16
   PubMed Web of Science ®Google Scholar
• Bin-Mahfoodh M, Hamani C, Sime E, et al. Longevity of batteries in internal pulse generators used for deep brain stimulation. Stereotact Func Neurosurg 2003;80:56-60
   PubMed Web of Science ®Google Scholar
• López Bastida J, Oliva J, Antonanzas F, et al. A proposed guideline for economic evaluation of health technologies. Gac Sanit 2010;24:154-70
   PubMed Web of Science ®Google Scholar
• Health Sector Economic Information. Spanish Cost Database, e-salud. Oblikue Consulting, Spain, 2010. http://www.oblikue.com/bddcostes/. Accessed February 2010
   Google Scholar
• Simoens S. Using the Delphi technique in economic evaluation: time to revisit the oracle? J Clin Pharm Ther 2006;31:519-22
   PubMed Web of Science ®Google Scholar
• McIntosh E, Gray A, Aziz T. Estimating the costs of surgical innovations: the case for subthalamic nucleus stimulation in the treatment of complicated Parkinson's Disease. Mov Disord 2003;18:993-9
   PubMedGoogle Scholar
• D'Ausilio A, Marconi S, Antonini A, et al. Cost analysis in Italy of various strategies for the treatment of Parkinson disease in the advanced phase. Recenti Prog Med 2003;94:484-93
   Google Scholar
• Tomaszewski K, Holloway R. Deep brain stimulation in the treatment of Parkinson's disease: a cost-effectiveness analysis. Neurology 2001;57:663-71
   PubMed Web of Science ®Google Scholar
• Valldeoriola F, Morsi O, Tolosa E, et al. Prospective comparative study on cost-effectiveness of subthalamic stimulation and best medical treatment in advanced Parkinson's disease. Mov Disord 2007;22:2183-91
   PubMed Web of Science ®Google Scholar
• Hollander M, Wolfe D. Nonparametric statistical methods. 2nd edn. Wiley Interscience, New York, NY, 1999
   Google Scholar
• Puig-Junoy J, Puig Peiró R. Review of the economic evidence on the use of deep brain stimulation in late stage Parkinson's disease. Neurologia 2009;24:220-9
   Google Scholar
• Gerzeli S, Cavallo M, Caprari F, et al. Analysis of deep brain stimulation (DBS) costs: an observational study on Italian patients. Pharmacoeconomics-Italian Research Articles 2002;4:66-79
   Google Scholar
• Charles P, Padaliya B, Newman A, et al. Deep brain stimulation of the subthalamic nucleus reduces antiparkinsonian medication costs. Parkisonism Relat Disord 2004;10:475-9
   PubMed Web of Science ®Google Scholar
• Fraix V, Houeto JL, Lagrange C, et al. Clinical and economic results of bilateral subthalamic nucleus stimulation in Parkinson's disease. J Neurol Neurosurg Psychiatry 2006;77:443-9
   PubMed Web of Science ®Google Scholar
• Spottke E, Volkmann J, Lorenz D, et al. Evaluation of healthcare utilization and health status of patients with Parkinson's disease treated with deep brain stimulation of the subthalamic nucleus. J Neurol 2002;249:759-66
   PubMed Web of Science ®Google Scholar
• Meissner W, Schreiter D, Volkmann J, et al. Deep brain stimulation in late stage Parkinson's disease: a retrospective cost analysis in Germany. J Neurol 2005;252:218-23
   PubMed Web of Science ®Google Scholar
• National Collaborating Centre for Chronic Conditions. Parkinson's Disease: national clinical guideline for diagnosis and management in primary and secondary care. Appendix F: 187–193. London: Royal College of Physicians, 2006
   Google Scholar
• Sydow O. Parkinson's disease: recent development in therapies for advanced disease with a focus on deep brain stimulation (DBS) and duodenal levodopa infusion. FEBS J 2008;275:1370-6
   Google Scholar